{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:20:26Z","timestamp":1788373226141,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["CL\u20102022\u201004\u2010004"],"award-info":[{"award-number":["CL\u20102022\u201004\u2010004"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pathological assessment of cystectomy specimens is important for accurate prognostic information and to inform adjuvant therapy decisions. However, there is limited evidence regarding the best approach to fixation, dissection, block selection and microscopic assessment of cystectomies. We report the results of an international survey of 212 pathologists and their approach to cystectomy pathology. There is variation at all stages of the specimen journey including in fixation and dissection techniques, and in the approach to evaluating residual tumour. This is particularly evident in the post-neoadjuvant chemotherapy setting where there is variable use of response scoring systems and differing approaches to sampling. We also find variation in the use of digital and molecular pathology in cystectomy specimens. Finally, we have suggested areas for future research in cystectomy pathological assessment.<\/jats:p>","DOI":"10.1007\/s00428-024-03924-3","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T06:02:12Z","timestamp":1725688932000},"page":"879-888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Variation in cystectomy pathology reporting practice\u2014results from an international survey of 212 pathologists"],"prefix":"10.1007","volume":"485","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3969-7637","authenticated-orcid":false,"given":"Jon","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comperat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"3924_CR1","unstructured":"Witjes J, Bruins HM, R C, Cathomas R, Comperat E, Efstathiou JA, et al (2024) EAU guidelines on muscle-invasive and metastatic bladder cancer. European association of urology. https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"3924_CR2","unstructured":"Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (2022) National institute for health and care excellence. https:\/\/www.nice.org.uk\/guidance\/TA817"},{"issue":"2","key":"3924_CR3","doi-asserted-by":"publisher","first-page":"107.e9","DOI":"10.1016\/j.urolonc.2022.09.013","volume":"41","author":"A Douglawi","year":"2023","unstructured":"Douglawi A, Ghoreifi A, Lee R, Ladi-Seyedian S-S, Alsyouf M, Ahmadi H et al (2023) Recurrence patterns in bladder cancer patients with no residual disease (pT0N0) at radical cystectomy: a 20-year experience. Urol Oncol: Semin Original Inv 41(2):107.e9-107.e14","journal-title":"Urol Oncol: Semin Original Inv"},{"issue":"3","key":"3924_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/PAS.0000000000000142","volume":"38","author":"A Fleischmann","year":"2014","unstructured":"Fleischmann A, Thalmann GN, Perren A, Seiler R (2014) Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. Am J Surg Pathol 38(3):325\u2013332","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"3924_CR5","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1097\/PAS.0000000000001371","volume":"43","author":"CS Voskuilen","year":"2019","unstructured":"Voskuilen CS, Oo HZ, Genitsch V, Smit LA, Vidal A, Meneses M et al (2019) Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Am J Surg Pathol 43(12):1600\u20131610","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"3924_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00345-021-03831-1","volume":"40","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Oszwald A, Wasinger G, Hansel DE, Montironi R, van der Kwast T et al (2022) Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World J Urol 40(4):915\u2013927","journal-title":"World J Urol"},{"key":"3924_CR7","unstructured":"R Core Team (2013). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/."},{"key":"3924_CR8","doi-asserted-by":"crossref","unstructured":"Hussain SA, Oughton JB, Smith Whelan R, Green A, Hubbard R, Kennish S, et al. (2024) INVEST: a phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. J Clin Oncol. 42(4_suppl):TPS710\u2013TPS710.","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS710"},{"issue":"6","key":"3924_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/jcp.2009.071191","volume":"63","author":"A Chandra","year":"2010","unstructured":"Chandra A, Griffiths D, McWilliam LJ (2010) Best practice: gross examination and sampling of surgical specimens from the urinary bladder. J Clin Pathol 63(6):475\u2013479","journal-title":"J Clin Pathol"},{"key":"3924_CR10","unstructured":"Murali DV, Shanks DJH, Chandra DA, McWilliam DL (2021) Dataset for histopathological reporting of tumours of the urinary collecting system (renal pelvis , ureter , urinary bladder and urethra). Royal College of Pathologists. https:\/\/www.rcpath.org\/profession\/guidelines\/cancer-datasets-and-tissue-pathways.html"},{"issue":"4","key":"3924_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00428-015-1726-7","volume":"466","author":"NT Gaisa","year":"2015","unstructured":"Gaisa NT, Wilms H, Wild PJ, Jakse G, Heidenreich A, Knuechel R (2015) In cystectomy specimens with bladder cancer whole organ embedding increases the detection rate of histopathological parameters, but not of those with prognostic significance. Virchows Archiv\u202f: Int J Pathol 466(4):423\u2013432","journal-title":"Virchows Archiv : Int J Pathol"},{"issue":"5","key":"3924_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/ajcp\/aqad176","volume":"161","author":"KE Saunders","year":"2024","unstructured":"Saunders KE, Gerken N, Khani F, Williamson SR, Wobker SE (2024) Current gross examination and reporting patterns of post\u2013neoadjuvant chemotherapy cystectomy specimens: is it time for a standardized approach? Am J Clin Pathol 161(5):483\u2013489","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"3924_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65(2):350\u2013357","journal-title":"Eur Urol"},{"key":"3924_CR14","doi-asserted-by":"publisher","unstructured":"Athanazio DA, Amorim LS, Werneck I, T\u00e1vora F, Cavalcanti MS, Bezerra SM, et al (2024) Handling and pathology reporting guidelines for bladder epithelial neoplasms \u2013 recommendations from the Brazilian Society of Pathology \/ Brazilian Society of Urology \/ Brazilian Society of Clinical Oncology. Surg Exp Pathol. https:\/\/doi.org\/10.1186\/s42047-024-00151-7","DOI":"10.1186\/s42047-024-00151-7"},{"issue":"5","key":"3924_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1470-2045(22)00158-9","volume":"23","author":"SA Hussain","year":"2022","unstructured":"Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A et al (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol 23(5):650\u2013658","journal-title":"Lancet Oncol"},{"issue":"2","key":"3924_CR16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I et al (2022) Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 82(2):212\u2013222","journal-title":"Eur Urol"},{"issue":"12","key":"3924_CR17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","volume":"26","author":"J Gao","year":"2020","unstructured":"Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS et al (2020) Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845\u20131851","journal-title":"Nat Med"},{"key":"3924_CR18","doi-asserted-by":"crossref","unstructured":"Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, et al (2023) Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol Oct 4;","DOI":"10.1200\/JCO.23.00307"},{"key":"3924_CR19","first-page":"1","volume":"2","author":"B Langlais","year":"2024","unstructured":"Langlais B, Dueck AC, Kosiorek HE, Mead-Harvey C, Meek E, Rogak L et al (2024) Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms. Leuk Lymphoma 2:1\u20139","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"3924_CR20","doi-asserted-by":"publisher","first-page":"e0303103","DOI":"10.1371\/journal.pone.0303103","volume":"19","author":"B Vanden Berghen","year":"2024","unstructured":"Vanden Berghen B, Vanermen I, Vranken L (2024) Citizen scientists: unveiling motivations and characteristics influencing initial and sustained participation in an agricultural project. PLoS ONE 19(5):e0303103","journal-title":"PLoS ONE"},{"key":"3924_CR21","doi-asserted-by":"publisher","unstructured":"Taze D, Chakrabarty A, Venkateswaran R, Hartley C, Harden C, Morgan AW, et al (2023) Histopathology reporting of temporal artery biopsy specimens for giant cell arteritis: results of a modified Delphi study. Journal of Clinical Pathology.;1\u20137. https:\/\/doi.org\/10.1136\/jcp-2023-208810","DOI":"10.1136\/jcp-2023-208810"},{"issue":"2","key":"3924_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/his.14650","volume":"81","author":"D Taze","year":"2022","unstructured":"Taze D, Hartley C, Morgan AW, Chakrabarty A, Mackie SL, Griffin KJ (2022) Developing consensus in histopathology: the role of the Delphi method. Histopathology 81(2):159\u2013167","journal-title":"Histopathology"},{"key":"3924_CR23","doi-asserted-by":"crossref","unstructured":"Griffin J, Down J, Quayle LA, Heath PR, Gibb EA, Davicioni E, et al (2024) Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. J Pathol: Clin Res 10(2)","DOI":"10.1002\/2056-4538.12363"},{"issue":"7","key":"3924_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/his.14087","volume":"76","author":"M Varma","year":"2020","unstructured":"Varma M, Delahunt B, McCluggage WG, Shah VI, Berney DM (2020) Macroscopy under the microscope: a critical reappraisal of grossing techniques. Histopathology 76(7):930\u2013933","journal-title":"Histopathology"},{"issue":"3","key":"3924_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1136\/jcp-2023-209045","volume":"77","author":"M Varma","year":"2023","unstructured":"Varma M, Collins LC, Chetty R, Karamchandani DM, Talia K, Dormer J et al (2023) Macroscopic examination of pathology specimens: a critical reappraisal. J Clin Pathol 77(3):164\u2013168","journal-title":"J Clin Pathol"},{"issue":"9666","key":"3924_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(09)60485-2","volume":"373","author":"P Quirke","year":"2009","unstructured":"Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J et al (2009) Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373(9666):821\u2013828","journal-title":"Lancet"},{"issue":"5","key":"3924_CR27","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00428-022-03287-7","volume":"480","author":"L Slumstrup","year":"2022","unstructured":"Slumstrup L, Eiholm S, Bennedsen ALB, Jepsen DNM, G\u00f6genur I, Fiehn AMK (2022) Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment. Virchows Arch 480(5):1041\u20131049","journal-title":"Virchows Arch"},{"issue":"2","key":"3924_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12029-019-00331-9","volume":"51","author":"LS Lino-Silva","year":"2020","unstructured":"Lino-Silva LS, Guzm\u00e1n-L\u00f3pez JC, Salazar-Garc\u00eda JA, Ch\u00e1vez-Hern\u00e1ndez JD, Gamboa-Dom\u00ednguez A, Chiquete E et al (2020) Interobserver variability in assessing pathologic response to preoperative treatment in rectal cancer: standardization of an evaluation method and comparisons between published scales. J Gastrointest Cancer 51(2):709\u2013713","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"3924_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D et al (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23(1):149\u2013160","journal-title":"Lancet Oncol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03924-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03924-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:04:27Z","timestamp":1731629067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03924-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["3924"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03924-3","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants gave informed consent to complete the questionnaire and the study received ethical approval from the University of Sheffield (UK) Ethics Committee on 24th July 2023 (approval number: 054611).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}